Neuroprotective action of agonists and modulators of A 1 adenosine receptors upon hyperexcitation: mechanism of the antiepileptic activity and role of neuron-glial interaction

Abstract

Hyperexcitation of neuronal networks is believed to be the main reason for the excitotoxic death of neurons in different central nervous system pathologies, including epilepsy, ischemic stroke, and traumatic brain injury. Gi-coupled receptors can be considered as promising targets for the development of new neuroprotectors. Here, we studied the anticonvulsant activity of the agonists and positive allosteric modulators (PAM) of A1 adenosine receptors (A1Rs). Our experiments demonstrate that A1R agonists, CCPA and N6-cyclohexyladenosine (N6-CHA), suppress hyperexcitation in three different in vitro models, including acute glutamate excitotoxicity, NH4Cl- and bicuculline-induced epileptiform activity. We have found that the inhibitory action of the agonists is mediated by the activation of not only the neuronal A1Rs but also the astrocytic receptors. In astrocytes, A1R agonists enhance GABA release, possibly via induction of calcium transients. Using inhibitory analysis, we have demonstrated that G{beta}{gamma}-mediated activation of phospholipase C and subsequent Ca2+ mobilization from internal stores are essential for generating calcium transients in astrocytes following N6-CHA application. We have shown first that Ca2+-dependent activation of protein kinase C, which is involved in the mechanism of GABA release by astrocytes, is a pivotal step in the realization of the antiepileptic action of A1R agonists. Moreover, using the model of epileptiform activity induced by GABAAR blockade, we have shown that PAMs, PD81723 and VCP171, also suppress hyperexcitation. Furthermore, using the picrotoxin-induced epilepsy model in mice, we demonstrated that A1R agonists exhibit significant anticonvulsant effects and improve animal survival. The PAMs PD81723 and VCP171, when administered one hour before seizure induction, did not significantly affect seizure severity or survival rates. However, chronic administration of VCP171 produced a pronounced anticonvulsant effect and significantly increased survival.. Importantly, PAMs provided therapeutic benefits without significantly affecting overall activity levels in mice. Thus, our study demonstrates that both agonists and PAMs of A1R can be considered as potential therapeutic agents with antiepileptic and neuroprotective activity.